{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:59:58Z","timestamp":1792699198356,"version":"4.5.0"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000582","name":"Carnegie Trust for the Universities of Scotland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>In recent years Scotland has been experiencing a disproportionally high number of drug related deaths compared to other European countries, causing significant individual, societal and economic burden. A possible cause of this is the increase in average number of substances involved in Scottish drug related deaths, as well as the changing pattern of substances involved. Opioids, cocaine, and alcohol have been consistently involved in the culture of drug use in Scotland, however recently National Records Scotland have identified that designer benzodiazepines such as etizolam, and prescription drugs such as gabapentinoids are increasingly being detected in Scottish toxicology reports. A systematic literature review following PRISMA guidelines was conducted through searching PubMed and Google Scholar to identify peer-reviewed articles published in English between 2013 and 2023 that investigated Scottish population data on gabapentinoids and etizolam to establish their contribution to the rise in Scottish drug related deaths. 18 studies were included in the review. A high use prevalence of etizolam and gabapentinoids in Scotland has been identified, with both substance-related deaths showing recent increase, marked since 2015. This pattern is replicated in the Scottish prison system. There has also been a significant increase of gabapentinoids prescriptions in Scotland. Polydrug use was identified as the most common determinant of both etizolam and gabapentinoids related adverse effects and fatality in Scotland, especially concurrent opioid use. The results indicate the literature on individual characteristics of Scottish at-risk users of gabapentinoids and etizolam is limited, however the data shows both substances are being used by older cohort, with adverse effects seen more in older women.<\/jats:p>","DOI":"10.1371\/journal.pone.0310655","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T17:23:24Z","timestamp":1728494604000},"page":"e0310655","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systematic review: The relationship between gabapentinoids, etizolam, and drug related deaths in Scotland"],"prefix":"10.1371","volume":"19","author":[{"given":"Beata","family":"Ciesluk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dr. Greig","family":"Inglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-6308","authenticated-orcid":true,"given":"Adrian","family":"Parke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6992-498X","authenticated-orcid":true,"given":"Lucy J.","family":"Troup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"issue":"7","key":"pone.0310655.ref001","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/S2468-2667(23)00082-8","article-title":"Mortality among individuals prescribed opioid-agonist therapy in Scotland, UK, 2011\u201320: a national retrospective cohort study","volume":"8","author":"A McAuley","year":"2023","journal-title":"The Lancet Public Health"},{"key":"pone.0310655.ref002","unstructured":"National Records of Scotland. Drug-related deaths in Scotland in 2021. NRS. Edinburgh; 2022."},{"issue":"10208","key":"pone.0310655.ref003","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action","volume":"394","author":"L Degenhardt","year":"2019","journal-title":"The Lancet"},{"key":"pone.0310655.ref004","unstructured":"House of Commons Scottish Affairs Committee. Problem drug use in Scotland: First Report of Session 2019. Available from: https:\/\/publications.parliament.uk\/pa\/cm201919\/"},{"key":"pone.0310655.ref005","article-title":"Opioid\u2010related deaths and their counterpart by occurrence era, age group and complicated drugs: Scotland vs. England and Wales","author":"SM Bird","year":"2024","journal-title":"British Journal of Clinical Pharmacology"},{"key":"pone.0310655.ref006","doi-asserted-by":"crossref","first-page":"103512","DOI":"10.1016\/j.drugpo.2021.103512","article-title":"From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic.","volume":"100","author":"A McAuley","year":"2022","journal-title":"International Journal of Drug Policy"},{"key":"pone.0310655.ref007","year":"2020","journal-title":"Drug-related deaths in Scotland in 2019"},{"key":"pone.0310655.ref008","unstructured":"EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). European Drug Report 2021: Trends and Developments; EMCDDA: Luxembourg; 2021."},{"key":"pone.0310655.ref009","unstructured":"UNODC. World Drug Report 2023. (United Nations Publication, 2023). 2023. Available online: https:\/\/www.unodc.org\/res\/ WDR-2023\/WDR23_Exsum_fin_SP.pdf"},{"issue":"1","key":"pone.0310655.ref010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/pharmacy12010013","article-title":"Benzodiazepine Boom: Tracking etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques.","volume":"12","author":"A Mullin","year":"2024","journal-title":"Pharmacy"},{"issue":"4","key":"pone.0310655.ref011","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"CM Jones","year":"2015","journal-title":"American journal of preventive medicine"},{"issue":"23","key":"pone.0310655.ref012","doi-asserted-by":"crossref","first-page":"14619","DOI":"10.3390\/ijms232314619","article-title":"Molecular insights and clinical outcomes of drugs of abuse adulteration: new trends and new psychoactive substances","volume":"23","author":"A Di Trana","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"pone.0310655.ref013","article-title":"Benzodiazepine Use\u2014Current Trends. Evidence Review; Scottish Government","author":"DGHSC (Director General Health and Social Care).","year":"2022"},{"key":"pone.0310655.ref014","volume-title":"Drug-related deaths in Scotland in 2018","author":"National Records of Scotland","year":"2019"},{"issue":"2","key":"pone.0310655.ref015","first-page":"88","article-title":"Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions","volume":"49","author":"E Sanna","year":"1999","journal-title":"Arzneimittel-Forschung"},{"key":"pone.0310655.ref016","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1016\/S0924-977X(99)00053-X","article-title":"The use and development of anxiolytics in Japan","volume":"9","author":"S. Yamawaki","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"4","key":"pone.0310655.ref017","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/17425255.2013.759209","article-title":"Understanding the pharmacokinetics of anxiolytic drugs","volume":"9","author":"AC Altamura","year":"2013","journal-title":"Expert opinion on drug metabolism & toxicology"},{"issue":"4","key":"pone.0310655.ref018","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/dar.13052","article-title":"Etizolam: a rapid review on pharmacology, non\u2010medical use and harms.","volume":"39","author":"S Nielsen","year":"2020","journal-title":"Drug and Alcohol Review"},{"key":"pone.0310655.ref019","unstructured":"WHO (World Health Organisation). Critical Review Report: ETIZOLAM; 2019."},{"key":"pone.0310655.ref020","unstructured":"WEDINOS (Welsh Emerging Drugs & Identification of Novel Substances). Annual Report: April 2022\u2013March 2023. 2023."},{"key":"pone.0310655.ref021","first-page":"2018","volume-title":"Review of the Psychoactive Act 2016.","author":"Home Office"},{"issue":"6","key":"pone.0310655.ref022","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/eurpub\/ckac161","article-title":"Evidence of the emergence of illicit benzodiazepines from online drug forums","volume":"32","author":"A Sarker","year":"2022","journal-title":"European Journal of Public Health"},{"issue":"6","key":"pone.0310655.ref023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.psym.2019.02.007","article-title":"Novel ways to acquire designer benzodiazepines: A case report and discussion of the changing role of the internet.","volume":"60","author":"AP Shapiro","year":"2019","journal-title":"Psychosomatics"},{"key":"pone.0310655.ref024","unstructured":"WEDINOS (Welsh Emerging Drugs & Identification of Novel Substances) Annual Report: April 2021\u2013March 2022. 2022."},{"key":"pone.0310655.ref025","article-title":"Investigating the role of benzodiazepines in drug-related mortality: a systematic review undertaken on behalf of the Scottish National Forum on Drug-Related Deaths.","author":"CF Johnson","year":"2016"},{"key":"pone.0310655.ref026","first-page":"116","article-title":"Benzodiazepines: an overview.","volume":"23","author":"D Dikeos","year":"2008","journal-title":"Sleep Disorders."},{"key":"pone.0310655.ref027","article-title":"The National Drug-related deaths Database (Scotland) report: analysis of deaths occurring in 2015 and 2016.","author":"L Barnsdale","year":"2018","journal-title":"Information Services Division Scotland"},{"issue":"3","key":"pone.0310655.ref028","doi-asserted-by":"crossref","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","article-title":"Benzodiazepine use, misuse, and abuse: a review.","volume":"6","author":"A. Schmitz","year":"2016","journal-title":"Mental Health Clinician."},{"issue":"7","key":"pone.0310655.ref029","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1093\/jat\/bkaa146","article-title":"A case series of etizolam in opioid-related deaths","volume":"45","author":"J Gevorkyan","year":"2021","journal-title":"Journal of Analytical Toxicology"},{"key":"pone.0310655.ref030","first-page":"403","article-title":"Abuse and misuse of pregabalin and gabapentin.","volume":"77","author":"KE Evoy","year":"2017","journal-title":"DrugsMar"},{"issue":"11","key":"pone.0310655.ref031","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/14737175.2016.1202764","article-title":"Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use","volume":"16","author":"EP Calandre","year":"2016","journal-title":"Expert review of neurotherapeutics"},{"issue":"38","key":"pone.0310655.ref032","doi-asserted-by":"crossref","first-page":"12856","DOI":"10.1523\/JNEUROSCI.2700-10.2010","article-title":"The \u03b12\u03b4 ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit \u03b12\u03b4-2","volume":"30","author":"A Tran-Van-Minh","year":"2010","journal-title":"Journal of Neuroscience"},{"key":"pone.0310655.ref033","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","article-title":"A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.","volume":"49","author":"HN Bockbrader","year":"2010","journal-title":"Clinical pharmacokinetics."},{"issue":"9","key":"pone.0310655.ref034","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40263-014-0192-0","article-title":"Pregabalin: a review of its use in adults with generalized anxiety disorder.","volume":"28","author":"JE Frampton","year":"2014","journal-title":"CNS drugs."},{"key":"pone.0310655.ref035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: an analysis of the European Medicines Agency\u2019s \u2018Suspected Adverse Drug Reactions\u2019 database.","volume":"30","author":"S Chiappini","year":"2016","journal-title":"CNS drugs."},{"issue":"5","key":"pone.0310655.ref036","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain\u2014is increased prescribing a cause for concern?.","volume":"377","author":"CW Goodman","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"pone.0310655.ref037","article-title":"Neuropathic Pain in Adults: Pharmacological Management in Non-Specialist Settings.","author":"National Institute for Health Care and Excellence","year":"2020"},{"issue":"20","key":"pone.0310655.ref038","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.2018.12358","article-title":"Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993\u20132017.","volume":"320","author":"F Montastruc","year":"2018","journal-title":"Jama"},{"issue":"3","key":"pone.0310655.ref039","first-page":"198","article-title":"Role of pharmaco-vigilance to identify patients at risk of dependency or diversion of prescribed drugs (gabapentin).","volume":"21","author":"L Watret","year":"2018","journal-title":"The Diabetic Foot Journal"},{"issue":"4","key":"pone.0310655.ref040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4997\/jrcpe.2017.402","article-title":"Gabapentin and pregabalin: do the benefits outweigh the harms","volume":"47","author":"EE Morrison","year":"2017","journal-title":"Journal of the Royal College of Physicians of Edinburgh"},{"issue":"12","key":"pone.0310655.ref041","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"U Bonnet","year":"2017","journal-title":"European neuropsychopharmacology"},{"key":"pone.0310655.ref042","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin: a systematic review.","volume":"30","author":"O Schjerning","year":"2016","journal-title":"CNS drugs."},{"issue":"1","key":"pone.0310655.ref043","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bcp.12277","article-title":"Misuse of the \u03b3-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK","volume":"78","author":"V. Kapil","year":"2014","journal-title":"British journal of clinical pharmacology"},{"key":"pone.0310655.ref044","doi-asserted-by":"crossref","first-page":"676224","DOI":"10.3389\/fpsyt.2021.676224","article-title":"Non-medical use of prescription gabapentinoids (gabapentin and pregabalin) in five European countries.","volume":"12","author":"F Fonseca","year":"2021","journal-title":"Frontiers in psychiatryApr 28"},{"issue":"10","key":"pone.0310655.ref045","doi-asserted-by":"crossref","first-page":"e1002396","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case\u2013control study.","volume":"14","author":"T Gomes","year":"2017","journal-title":"PLoS medicine.Oct 3"},{"issue":"1","key":"pone.0310655.ref046","doi-asserted-by":"crossref","first-page":"e023600","DOI":"10.1136\/bmjopen-2018-023600","article-title":"Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials.","volume":"9","author":"IJ Onakpoya","year":"2019","journal-title":"BMJ open"},{"key":"pone.0310655.ref047","first-page":"364","article-title":"Pregabalin and gabapentin: what impact will reclassification have on doctors and patients?.","author":"I. Torjesen","year":"2019","journal-title":"BMJ: British Medical Journal (Online)."},{"issue":"8","key":"pone.0310655.ref048","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1111\/bcp.15352","article-title":"Fatalities associated with gabapentinoids in England (2004\u20132020).","volume":"88","author":"NJ Kalk","year":"2022","journal-title":"British journal of clinical pharmacology"},{"issue":"1","key":"pone.0310655.ref049","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1037\/adb0000337","article-title":"A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.","volume":"32","author":"R Vickers Smith","year":"2018","journal-title":"Psychology of Addictive Behaviors.Feb"},{"issue":"7","key":"pone.0310655.ref050","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review.","volume":"111","author":"RV Smith","year":"2016","journal-title":"AddictionJul"},{"issue":"8","key":"pone.0310655.ref051","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1111\/bcp.14715","article-title":"Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non\u2010cancer pain: a five\u2010year prospective cohort study","volume":"87","author":"S Nielsen","year":"2021","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"pone.0310655.ref052","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/add.13843","article-title":"Risk to heroin users of polydrug use of pregabalin or gabapentin.","volume":"112","author":"A Lyndon","year":"2017","journal-title":"Addiction"},{"issue":"2","key":"pone.0310655.ref053","first-page":"67","article-title":"Pregabalin as adjunctive therapy in benzodiazepine discontinuation.","volume":"75","author":"K Caniff","year":"2018","journal-title":"The Bulletin of the American Society of Hospital Pharmacists."},{"issue":"4","key":"pone.0310655.ref054","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11126-016-9421-7","article-title":"Abuse of gabapentin is associated with opioid addiction.","volume":"87","author":"L Bastiaens","year":"2016","journal-title":"Psychiatric Quarterly."},{"key":"pone.0310655.ref055","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"M Grosshans","year":"2013","journal-title":"European journal of clinical pharmacology"},{"issue":"12","key":"pone.0310655.ref056","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1111\/bcp.14348","article-title":"Pregabalin poisoning and rising recreational use: a retrospective observational series","volume":"86","author":"KZ Isoardi","year":"2020","journal-title":"British journal of clinical pharmacology"},{"key":"pone.0310655.ref057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"M H\u00e4kkinen","year":"2014","journal-title":"Forensic science international"},{"key":"pone.0310655.ref058","article-title":"Pregabalin abuse amongst opioid substitution treatment patients.","author":"S McNamara","year":"2015"},{"issue":"3","key":"pone.0310655.ref059","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/brainsci10030142","article-title":"Exploring the baseline knowledge and experience of healthcare professionals in the United Kingdom on novel psychoactive substances","volume":"10","author":"C Ramos","year":"2020","journal-title":"Brain Sciences"},{"issue":"3","key":"pone.0310655.ref060","first-page":"467","article-title":"Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews.","volume":"21","author":"Z Munn","year":"2023","journal-title":"JBI Evidence Synthesis.Mar 1"},{"key":"pone.0310655.ref061","first-page":"7","article-title":"XT Zeng Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better?.,","author":"LL Ma","year":"2020"},{"issue":"1","key":"pone.0310655.ref062","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40545-021-00350-7","article-title":"A mixed-methods systematic review of the prevalence, reasons, associated harms and risk-reduction interventions of over-the-counter (OTC) medicines misuse, abuse and dependence in adults.","volume":"14","author":"M Algarni","year":"2021","journal-title":"Journal of pharmaceutical policy and practice"},{"key":"pone.0310655.ref063","doi-asserted-by":"crossref","first-page":"725034","DOI":"10.3389\/fphar.2021.725034","article-title":"Relationship between cardiovascular disease pathology and fatal opioid and other sedative overdose: a post-mortem investigation and pilot study.","volume":"12","author":"AZ Arab","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"pone.0310655.ref064","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.","volume":"20","author":"CR Baird","year":"2014","journal-title":"European addiction research."},{"issue":"20","key":"pone.0310655.ref065","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1039\/C5AY01711D","article-title":"A preliminary investigation to group disparate batches of licit and illicit diazepam tablets using differential scanning calorimetry.","volume":"7","author":"S Bibi","year":"2015","journal-title":"Analytical methods."},{"issue":"11","key":"pone.0310655.ref066","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2174\/1570159X20666220830110758","article-title":"Contribution of Drugs to Drowning in Scotland from 1996 to 2020","volume":"21","author":"JM Corkery","year":"2023","journal-title":"Current neuropharmacology"},{"issue":"9","key":"pone.0310655.ref067","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/02698811221104065","article-title":"Alprazolam-related deaths in Scotland, 2004\u20132020.","volume":"36","author":"JM Corkery","year":"2022","journal-title":"Journal of psychopharmacology."},{"issue":"3","key":"pone.0310655.ref068","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bcp.14183","article-title":"How deaths can help clinicians and policy\u2010makers understand the risks of novel psychoactive substances","volume":"86","author":"JM Corkery","year":"2020","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"pone.0310655.ref069","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/20494637221095447","article-title":"Characteristics of non-fatal overdoses and associated risk factors in patients attending a specialist community-based substance misuse service","volume":"16","author":"R Ghose","year":"2022","journal-title":"British Journal of Pain"},{"key":"pone.0310655.ref070","doi-asserted-by":"crossref","first-page":"732345","DOI":"10.3389\/fphar.2021.732345","article-title":"Opioids and gabapentinoids utilisation and their related-mortality trends in the United Kingdom primary care setting, 2010\u20132019: a cross-national, population-based comparison study.","volume":"12","author":"A. Kurdi","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"pone.0310655.ref071","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12954-023-00771-4","article-title":"Baseline characteristics of people experiencing homelessness with a recent drug overdose in the PHOENIx pilot randomised controlled trial","volume":"20","author":"R Lowrie","year":"2023","journal-title":"Harm reduction journal"},{"key":"pone.0310655.ref072","article-title":"Changing trends in novel benzodiazepine use within Scottish prisons: detection, quantitation, prevalence, and modes of use.","author":"V Marland","year":"2023","journal-title":"Drug Testing and Analysis"},{"issue":"5","key":"pone.0310655.ref073","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.drugpo.2014.10.010","article-title":"Mortality related to novel psychoactive substances in Scotland, 2012: an exploratory study","volume":"26","author":"A. McAuley","year":"2015","journal-title":"International Journal of Drug Policy"},{"key":"pone.0310655.ref074","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.forsciint.2015.08.008","article-title":"A review of ethylphenidate in deaths in east and west Scotland","volume":"257","author":"C Parks","year":"2015","journal-title":"Forensic Science International"},{"issue":"8","key":"pone.0310655.ref075","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1111\/bcp.14727","article-title":"Trends in new prescription of gabapentinoids and of coprescription with opioids in the 4 nations of the UK, 1993\u20132017.","volume":"87","author":"A Rahman","year":"2021","journal-title":"British journal of clinical pharmacology"},{"key":"pone.0310655.ref076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-021-11162-4","article-title":"Quantifying prescribed high dose opioids in the community and risk of overdose.","volume":"21","author":"J Schofield","year":"2021","journal-title":"BMC public health."},{"issue":"2","key":"pone.0310655.ref077","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bja.2020.05.017","article-title":"Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland","volume":"125","author":"N Torrance","year":"2020","journal-title":"British journal of anaesthesia"},{"issue":"1","key":"pone.0310655.ref078","first-page":"62","article-title":"Why are drug-related deaths among women increasing in Scotland? A mixed-methods analysis of possible explanations.","volume":"29","author":"EJ Tweed","year":"2022","journal-title":"Drugs: Education, Prevention and Policy.2"},{"issue":"6","key":"pone.0310655.ref079","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000516165","article-title":"Explaining the differences in opioid overdose deaths between Scotland and England\/Wales: implications for European opioid policies.","volume":"27","author":"J van Amsterdam","year":"2021","journal-title":"European Addiction Research."},{"issue":"8","key":"pone.0310655.ref080","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/dta.3263","article-title":"NPS detection in prison: A systematic literature review of use, drug form, and analytical approaches.","volume":"14","author":"G Vaccaro","year":"2022","journal-title":"Drug testing and analysis"},{"issue":"3","key":"pone.0310655.ref081","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00097-8","article-title":"Guidelines and methodological reviews concerning drug abuse liability assessment","volume":"70","author":"RL Balster","year":"2003","journal-title":"Drug and alcohol dependence"},{"issue":"1","key":"pone.0310655.ref082","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/papr.13165","article-title":"Gabapentin\u2014Friend or foe?.","volume":"23","author":"M Russo","year":"2023","journal-title":"Pain Practice"},{"key":"pone.0310655.ref083","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuro.2019.02.015","article-title":"An expanding world of new psychoactive substances\u2014designer benzodiazepines","volume":"73","author":"JB Zawilska","year":"2019","journal-title":"Neurotoxicology"},{"issue":"4","key":"pone.0310655.ref084","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.amepre.2021.08.024","article-title":"Concurrent use of prescription opioids and gabapentinoids in older adults","volume":"62","author":"C Chen","year":"2022","journal-title":"American journal of preventive medicine"},{"key":"pone.0310655.ref085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2019.12.007","article-title":"Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification","volume":"110","author":"MD Stein","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"pone.0310655.ref086","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","article-title":"Current evidence on abuse and misuse of gabapentinoids.","volume":"43","author":"S H\u00e4gg","year":"2020","journal-title":"Drug safety.Dec"},{"key":"pone.0310655.ref087","first-page":"1","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study.","volume":"6","author":"WM Bramer","year":"2017","journal-title":"Systematic reviews.Dec"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T17:23:53Z","timestamp":1728494633000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310655"}},"subtitle":[],"editor":[{"given":"Mohammad","family":"Amrollahi-Sharifabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":87,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310655","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]}}}